|
FDA to rule on Glaxo-Theravance lung drug by May
Businessweek The companies have asked the FDA to approve Breo as a treatment for chronic obstructive pulmonary disease, and they want the European Medicines Agency to approve the drug as a treatment for COPD and asthma. The companies added that on Tuesday … GSK and Theravance Announce FDA Acceptance of FF/VI New Drug Application … GlaxoSmithKline, Theravance say FDA Accepts FF/VI NDA Submission For COPD GSK and Theravance make progress in FDA review of key COPD drug |
View full post on asthma – Google News